212 related articles for article (PubMed ID: 16596817)
1. Protection of endothelial function.
Spieker LE; Lüscher TF
Handb Exp Pharmacol; 2005; (170):619-44. PubMed ID: 16596817
[TBL] [Abstract][Full Text] [Related]
2. Protection of endothelial function: targets for nutritional and pharmacological interventions.
Sudano I; Spieker LE; Hermann F; Flammer A; Corti R; Noll G; Lüscher TF
J Cardiovasc Pharmacol; 2006; 47 Suppl 2():S136-50; discussion S172-6. PubMed ID: 16794451
[TBL] [Abstract][Full Text] [Related]
3. Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosis.
Spieker LE; Lüscher TF; Noll G
J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S35-41. PubMed ID: 11811375
[TBL] [Abstract][Full Text] [Related]
4. Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.
Lüscher TF; Yang Z
Drugs; 1993; 46 Suppl 2():121-32. PubMed ID: 7512465
[TBL] [Abstract][Full Text] [Related]
5. The vascular endothelium in hypertension.
Spieker LE; Flammer AJ; Lüscher TF
Handb Exp Pharmacol; 2006; (176 Pt 2):249-83. PubMed ID: 16999229
[TBL] [Abstract][Full Text] [Related]
6. Working under pressure: the vascular endothelium in arterial hypertension.
Spieker LE; Noll G; Ruschitzka FT; Maier W; Lüscher TF
J Hum Hypertens; 2000; 14(10-11):617-30. PubMed ID: 11095155
[TBL] [Abstract][Full Text] [Related]
7. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
Ruschitzka FT; Lüscher TF
Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
[TBL] [Abstract][Full Text] [Related]
8. Restoring the dysfunctional endothelium.
Osto E; Coppolino G; Volpe M; Cosentino F
Curr Pharm Des; 2007; 13(10):1053-68. PubMed ID: 17430168
[TBL] [Abstract][Full Text] [Related]
9. Current pharmacological approach to restore endothelial dysfunction.
Dobarro D; Gómez-Rubín MC; Sanchez-Recalde A; Moreno R; Galeote G; Jimenez-Valero S; Calvo L; López de Sá E; López-Sendón JL
Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):212-22. PubMed ID: 19689260
[TBL] [Abstract][Full Text] [Related]
10. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
Enseleit F; Hürlimann D; Lüscher TF
J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
[TBL] [Abstract][Full Text] [Related]
11. Endothelial dysfunction and vascular disease - a 30th anniversary update.
Vanhoutte PM; Shimokawa H; Feletou M; Tang EH
Acta Physiol (Oxf); 2017 Jan; 219(1):22-96. PubMed ID: 26706498
[TBL] [Abstract][Full Text] [Related]
12. Combination of ACE inhibitors and calcium antagonists: a logical approach.
Ruschitzka FT; Noll G; Lüscher TF
J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
Chłopicki S; Gryglewski RJ
Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
[TBL] [Abstract][Full Text] [Related]
14. Vascular protection: current possibilities and future perspectives.
Lüscher TF
Int J Clin Pract Suppl; 2001 Jan; (117):3-6. PubMed ID: 11715356
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
Tschudi MR; Noll G; Lüscher TP
Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between exogenous statins and endogenous high-density lipoprotein in anti-inflammatory and anti-atherogenic actions.
Kimura T; Sato K; Tomura H; Okajima F
Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):8-15. PubMed ID: 20105136
[TBL] [Abstract][Full Text] [Related]
17. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.
Landmesser U; Drexler H
J Hypertens Suppl; 2006 Mar; 24(1):S39-43. PubMed ID: 16601572
[TBL] [Abstract][Full Text] [Related]
18. Endothelium and atherogenesis: endothelial therapy revisited.
Barton M; Haudenschild CC
J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S23-5. PubMed ID: 11811371
[TBL] [Abstract][Full Text] [Related]
19. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide.
Taddei S; Virdis A; Ghiadoni L; Salvetti A
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S37-40. PubMed ID: 10976779
[TBL] [Abstract][Full Text] [Related]
20. The endothelium in coronary artery disease.
Ruschitzka FT; Noll G; Lüscher TF
Cardiology; 1997; 88 Suppl 3():3-19. PubMed ID: 9397288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
